Vistagen Reports P-III Trial (PALISADE-2) Results of Fasedienol (PH94B) Nasal Spray for Social Anxiety Disorder
Shots:
- The P-III trial evaluating fasedienol in 141 patients. The trial met their primary & secondary efficacy EPs i.e., a significant difference in avg. SUDS score during a public speaking challenge over PBO at Visit 3
- Significant difference in the proportion of clinician-assessed responders as measured by the CGI-I scale, was well-tolerated with consistent favorable safety profile with all prior trials. The trial also met an exploratory EPs of the difference in the proportion of patient-assessed responders as measured by the PGI-C scale, patients rated as responders (40.6% vs 18.6%)
- Difference in the proportion of patients with a 20-point improvement in patient-assessed SUDS score (Visit 2) to treatment (Visit 3), improvement in SUDS score (35.7% vs 18.6%), no AEs were reported
Ref: Vistagen | Image: Vistagen
Related News:- Vistagen Reports First Patient Dosing in P-I Study of PH10 to Treat Major Depressive Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
